Jacob Cookey1, Denise Bernier1, Philip G Tibbo2. 1. Department of Psychiatry, Dalhousie University, 5909 Veterans' Memorial Lane, 8th Floor, Rm. 8206 Abbie J. Lane Memorial Building, QEII Health Sciences Centre, Halifax, NS, Canada, B3H 2E2; Capital District Health Authority, Room 3030, 3rd Floor, AJLB, 5909 Veterans' Memorial Lane, Halifax, NS, Canada, B3H 2E2. 2. Department of Psychiatry, Dalhousie University, 5909 Veterans' Memorial Lane, 8th Floor, Rm. 8206 Abbie J. Lane Memorial Building, QEII Health Sciences Centre, Halifax, NS, Canada, B3H 2E2; Capital District Health Authority, Room 3030, 3rd Floor, AJLB, 5909 Veterans' Memorial Lane, Halifax, NS, Canada, B3H 2E2. Electronic address: phil.tibbo@cdha.nshealth.ca.
Abstract
OBJECTIVES: The impact of cannabis use on the brain tissue is still unclear, both in the healthy developing brain and in people with schizophrenia. The focus of this review is on white matter, the primary connective infrastructure of the brain. METHODS: We systematically reviewed diffusion tensor imaging (DTI) studies of early phase schizophrenia (illness effect), of cannabis use in otherwise healthy brains (drug effect), and of early phase schizophrenia with cannabis use (combined effects). Studies had to include a healthy, non-cannabis using, control group as well as report on fractional anisotropy as it is the most commonly used DTI index. We excluded cohorts with heavy alcohol or illicit drug use and studies with a sample size of less than 20 in the clinical group. RESULTS: We retained 17 studies of early phase schizophrenia, which together indicate deficits in white matter integrity observed in all fiber tract families, but most frequently in association, callosal and projection fibers. In otherwise healthy cannabis users (2 studies), deficits in white matter tracts were reported mainly in callosal fibers, but also in projection and limbic fibers. In cannabis users with early phase schizophrenia (1 study), deficits in white matter integrity were also observed in all fiber tract families, except for limbic fibers. CONCLUSIONS: The current literature points to several families of white matter tracts being differentially affected in early phase schizophrenia. Further work is required to reveal the impact of cannabis use in otherwise healthy people as well as those with schizophrenia. LIMITATIONS: Paucity of available studies as well as restricting analysis to FA values represent the main limitations of this review.
OBJECTIVES: The impact of cannabis use on the brain tissue is still unclear, both in the healthy developing brain and in people with schizophrenia. The focus of this review is on white matter, the primary connective infrastructure of the brain. METHODS: We systematically reviewed diffusion tensor imaging (DTI) studies of early phase schizophrenia (illness effect), of cannabis use in otherwise healthy brains (drug effect), and of early phase schizophrenia with cannabis use (combined effects). Studies had to include a healthy, non-cannabis using, control group as well as report on fractional anisotropy as it is the most commonly used DTI index. We excluded cohorts with heavy alcohol or illicit drug use and studies with a sample size of less than 20 in the clinical group. RESULTS: We retained 17 studies of early phase schizophrenia, which together indicate deficits in white matter integrity observed in all fiber tract families, but most frequently in association, callosal and projection fibers. In otherwise healthy cannabis users (2 studies), deficits in white matter tracts were reported mainly in callosal fibers, but also in projection and limbic fibers. In cannabis users with early phase schizophrenia (1 study), deficits in white matter integrity were also observed in all fiber tract families, except for limbic fibers. CONCLUSIONS: The current literature points to several families of white matter tracts being differentially affected in early phase schizophrenia. Further work is required to reveal the impact of cannabis use in otherwise healthy people as well as those with schizophrenia. LIMITATIONS: Paucity of available studies as well as restricting analysis to FA values represent the main limitations of this review.
Authors: Benedikt Fischer; Cayley Russell; Pamela Sabioni; Wim van den Brink; Bernard Le Foll; Wayne Hall; Jürgen Rehm; Robin Room Journal: Am J Public Health Date: 2017-06-23 Impact factor: 9.308
Authors: Daniel Bergé; Anna Mané; Tyler A Lesh; Miquel Bioque; Fe Barcones; Ana Maria Gonzalez-Pinto; Mara Parellada; Eduard Vieta; Josefina Castro-Fornieles; Roberto Rodriguez-Jimenez; Maria Paz García-Portilla; Judith Usall; Cameron S Carter; Bibiana Cabrera; Miguel Bernardo; Joost Janssen Journal: Schizophr Bull Date: 2020-07-08 Impact factor: 9.306
Authors: Jayachandra M Raghava; René C W Mandl; Mette Ø Nielsen; Birgitte Fagerlund; Birte Y Glenthøj; Egill Rostrup; Bjørn H Ebdrup Journal: Brain Imaging Behav Date: 2021-02 Impact factor: 3.978
Authors: Jie-Yu Chuang; Graham K Murray; Antonio Metastasio; Nuria Segarra; Roger Tait; Jenny Spencer; Hisham Ziauddeen; Robert B Dudas; Paul C Fletcher; John Suckling Journal: Front Psychiatry Date: 2014-08-27 Impact factor: 4.157